 BriaCell Therapeutics Corp NASDAQ: BCTX has advanced its targeted oncology therapeutics into several novel immunotherapy cell lines, including - Bria-Pros for prostate cancer, Bria-Mel for melanoma, and Bria-Lung for lung cancer. The company anticipates commencing clinical trials for these novel therapies in 2022. 